Taho Pharmaceuticals (ROCO:6467) PEG Ratio: N/A (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
35 GF Score
Price NT$110.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Taho Pharmaceuticals's PE Ratio without NRI is 0.00. Taho Pharmaceuticals's 5-Year EBITDA growth rate is -28.60%. Therefore, Taho Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Taho Pharmaceuticals's PEG Ratio or its related term are showing as below:



ROCO:6467's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.825
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Taho Pharmaceuticals  (ROCO:6467) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Taho Pharmaceuticals PEG Ratio Related Terms


Taho Pharmaceuticals PEG Ratio Historical Data

* Premium members only.

The historical data trend for Taho Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taho Pharmaceuticals PEG Ratio Chart

Taho Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Taho Pharmaceuticals Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ROCO:6467 vs ZTS, UTHR: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taho Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Taho Pharmaceuticals's PEG Ratio falls into.


ROCO:6467
35GF Score
Taho Pharmaceuticals Ltd ROCO:6467
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Taho Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-28.60
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score

Get the complete analysis for ROCO:6467

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$110.50
Price